 |
|
| Type | Public (NASDAQ: AMGN) |
|---|---|
| Founded | 1980 |
| Headquarters | Thousand Oaks, California |
| Key people | Kevin W. Sharer, President & CEO |
| Industry | Biotechnology |
| Products | Epogen, Aranesp, Kineret, Enbrel, Neulasta, Neupogen, and Sensipar / Mimpara |
| Revenue | ▲$14.771 Billion USD (2007) |
| Net income | ▲$3.166 Billion USD (2007) |
| Employees | 17,500 (2007) |
| Website | www.amgen.com |
Amgen Inc. (NASDAQ: AMGN, SEHK: 4332) is an international biotechnology company headquartered in Thousand Oaks, California. Located in the Conejo Valley, Amgen is the largest independent biotech firm. The company employs approximately 14,000 staff members including the 125 Allied-Barton Security staff and A-post personnel in 2007. Its products include Epogen, Aranesp, Enbrel, Kineret, Neulasta, Neupogen, Sensipar / Mimpara and Nplate. Epogen and Neupogen (the company's first products on the market) were the two most successful biopharmaceutical products at the time of their respective releases.
BusinessWeek ranked Amgen fourth on the S&P 500 for being the most "future-oriented" of those five hundred corporations.[1] BusinessWeek ostensibly calculated the ratio of research and development spending, combined with capital spending, to total outlays; Amgen had the fourth highest ratio, at 506:1000.
Amgen is the largest employer in Thousand Oaks and second only to the United States Navy in terms of number of people employed in Ventura County.
With plans to expand into a new campus under construction in South San Francisco, Amgen abruptly halted construction on the plans and instead put the 365,000 square feet (33,900 m2) of new space on the sublease market.[2]
In 2006, Amgen began sponsoring the Tour of California, one of only three major Union Cycliste Internationale events in the United States.
Contents |
History
The word AMGen is a portmanteau of the company's original name, Applied Molecular Genetics, which became the official name of the company in 1983 (three years after incorporation and coincident with its initial public offering). The company's first chief executive officer, from 1980, was George B. Rathmann, followed by Gordon M. Binder in 1988, followed by Kevin W. Sharer in 2000. The company has made at least five major corporate acquisitions.
Acquisition history
- 1994 - Synergen, Inc.
- 2000 - Kinetix Pharmaceuticals, Inc.
- 2002 - Immunex Corporation[3]
- 2004 - Tularik, Inc.
- 2006 - Abgenix, Inc.[4]
- 2006 - Avidia, Inc.
- 2007 - Ilypsa, Inc.
- 2007 - Alantos Pharmaceuticals Holdings, Inc.
Products
As of November 20, 2008, Amgen had ten approved drugs for fifteen conditions (conditions lists are highly generalized; see each article for more detail):
- Aranesp (darbepoetin alfa) (for anemia)
- Enbrel (Etanercept) (for various forms of arthritis)
- Epogen (Epoetin) (for anemia)
- Kepivance (Palifermin) (for oral mucositis)
- Kineret (Anakinra) (for rheumatoid arthritis)
- Neupogen (Granulocyte-Colony Stimulating Factor ) (for neutropenia)
- Neulasta (PEG Granulocyte-Colony Stimulating Factor or "Pegfilgrastim") (for neutropenia)
- Vectibix (Panitumumab) (for colon cancer)
- Sensipar (Cinacalcet) (for Secondary hyperparathyroidism, a mineral metabolism complication common in patients with kidney failure)
- Nplate (Romiplostim) (for chronic immune thrombocytopenic purpura)
In other drug discovery phases (Phases I, II, III and in preclinical development), the company has twenty-three pharmacologic agents for twenty-eight conditions; nineteen of the candidates are not currently approved for any indication. Precedent within the pharmaceutical industry suggests that few of these candidate drugs will emerge as marketed approved drugs.
References
- ^ Coy, Peter (2004-10-11). "The Search for Tomorrow". BusinessWeek. http://www.businessweek.com/@@UPQMFoUQ96PcERwA/magazine/content/04_41/b3903476.htm. access to article requires free registration on site
- ^ "Amgen Slows its Bay Area Expansion". San Francisco Business Times web site. http://www.bizjournals.com/sanfrancisco/stories/2007/08/13/story1.html. Retrieved August 14 2007.
- ^ http://www.amgen.com/media/media_pr_detail.jsp?year=2002&releaseID=515163
- ^ http://wwwext.amgen.com/media/media_pr_detail.jsp?year=2006&releaseID=837754
See also
- Kirin-Amgen v Hoechst Marion Roussel, a UK patent case decided by the House of Lords
External links
- Official website
- Company Profile at Pharmaceutical Business Review
- Amgen Inc. Company Profile Profile at Google Finance.
- Drivers for Amgen's acquisition of immunex
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
